Genmab — November 2019
-
Vi er ikke færdige med at lave håndtaget i koppen som The Note viste forleden, længere er den vist ikke....
-
Oral, trying to reduce steroids -
864 Phase 2 Trial of Daratumumab, Ixazomib, Lenalidomide and Modified Dose Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma https://ash.confex.com/ash/2019/webprogram/Paper131476.html -
Oral, we show an unprecedented 15/18 (83%) MRD negativity rate among newly diagnosed multiple myeloma patients - 862 Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) https://ash.confex.com/ash/2019/webprogram/Paper126378.html
-
Vitus... royaltyindtægter bliver offentligt ved regnskaber. Det er dokumentionen for investorerne. Guidingen indikerer hvor meget selskabet regner med at få i royalty i fremtiden. Det er først og fremmest det at investorer styrer efter.
-
En klog mand skrev engang her i chatten, at"når en aktie er boblet X 50, er det nok tiden at finde den næste, der kan gøre det, for den gør det ikke igen". Vi sidder her og hepper på fhv. små stigninger, mens andre aktier overhaler. Mine små Veloer overhaler snart - de er 6 doblet på de år,siden sidst Gen var i denne kurs. De fleste af os er her vist lige så meget af interesse.
-
Stockbull . Du må meget gerne lægge et screen dum af koppen med en kort forklaring i debatten. Altså hvis du har tid.
-
Oral, 150 Targeting Bcl-2 and CD38 As Part of Personalized HSCT Conditioning Regimen in Chemorefractory Acute Leukemia in Children https://ash.confex.com/ash/2019/webprogram/Paper129765.html
-
bikube..Jeg har fundet den slags mangedoblere i LPG. Velo har jeg desværre ikke rigtigt haft inde på radaren.
-
-
Poster Conclusion: Here we show for the first time that, although follow-up is still short, the combination of daratumumab and nivolumab may be a new therapeutic regimen with an acceptable safety profile in RRMM - 1879 Efficacy and Safety of Nivolumab Combined with Daratumumab - https://ash.confex.com/ash/2019/webprogram/Paper124339.html
-
Måske det er gammelt nyt her (?), men ellers en artikel fra oktober: "Enapotamab vedotin, an AXL-specific antibody-drug conjugate, shows preclinical antitumor activity in non-small cell lung cancer". https://insight.jci.org/articles/view/128199
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind